Clinical trials: in Algeria
Congenital Bleeding Disorder, Haemophilia A
Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors
This trial is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy of home treatment of joint bleeds (haemarthrosis) with NovoSeven® (activated recombinant human factor VII) in patients with haemophilia…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A, Haemophilia B
- Trial name
- NCT01234545
- Testing
- activated recombinant human factor VII
- Where
- 5 sites in Algeria, Morocco and 3 more
- Volunteers
- 35 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Evaluate the Safety and Efficacy of Levemir® in Type 2 Diabetes
This study is conducted in Africa. The aim of this study is to assess the safety and efficacy of Levemir® treatment for insulin naive patients with type 2 diabetes under normal clinical practice conditions in Algeria.
- Trial name
- IDEALS (NCT00700830)
- Testing
- insulin detemir
- Where
- Algeria
- Volunteers
- 1,976 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Primary Objective: To evaluate the efficacy of the association Lantus (once-a-day, od) Apidra (thrice-a-day, tid) in terms of change HbA1c from baseline to end of study (week 24), in patients with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- SUBSTITUTE (NCT01204593)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE
- Where
- 43 sites in Algeria, Argentina and 7 more
- Volunteers
- 206 people
- Sponsor
- Sanofi
Breast Cancer
H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer
This observational study will assess the safety of Herceptin (trastuzumab) in patients with HER2-positive breast cancer in routine clinical practice. Eligible patients will be followed for up to 4 years.
- Trial name
- NCT01991340
- Where
- 19 sites in Algeria, Morocco
- Volunteers
- 657 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs
Primary Objective: To evaluate the efficacy of an intensive insulin regimen with insulin glargine and insulin glulisine in terms of change in Hemoglobin A1c (HbA1c) level from week 12 (visit 7) to week 24 (visit 10).
- Trial name
- CHANGING (NCT01203111)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE
- Where
- 10 sites in Algeria, Brazil and 8 more
- Volunteers
- 207 people
- Sponsor
- Sanofi
Hypertension
ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination
To compare the antihypertensive efficacy of the combination irbesartan/hydrochlorothiazide (HCTZ) using either a usual or an active elective titration regimen.
- Trial name
- ACTUAL (NCT00708344)
- Testing
- Irbesartan - Hydrochlorothiazide
- Where
- 16 sites in Algeria, Argentina and 14 more
- Volunteers
- 832 people
- Sponsor
- Sanofi
Head and Neck Neoplasms
NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)
Primary Objective: To estimate the overall response rate after neo-adjuvant chemotherapy of Docetaxel 75 mg/m2 in combination with Cisplatin 75 mg/m2 given for 3 cycles, and followed by conventional radiotherapy in UCNT.
- Trial name
- NCT00916097
- Testing
- DOCETAXEL(XRP6976)
- Where
- 3 sites in Algeria, Morocco and 1 more
- Volunteers
- 66 people
- Sponsor
- Sanofi
Hypertension
APROVE : Irbesartan in Hypertension
Study objective : To compare efficacy and tolerability of posology adaptation of Irbesartan in ambulatory Hypertensive patients
- Trial name
- NCT00283036
- Testing
- Irbesartan
- Where
- Algeria
- Volunteers
- 200 people
- Sponsor
- Sanofi